Morgan Stanley has issued a report commenting on the start of the year for Thermo Fisher Scientific TMO.
In the report Morgan Stanley writes, "Against a challenging basis of comparison and amid concern about the quarter, 1Q showed solid operating performance with organic growth 100bps better than expectations and EPS upside driven by accelerating capital deployment on repurchases."
TMO is Overweight rated and closed at $58.08 yesterday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in